Clinical trial design for cutaneous neurofibromas
Neurology, 2018•AAN Enterprises
Objective Several clinical trials targeting cutaneous neurofibromas (cNF) have been
conducted; however, none has resulted in meaningful changes to care. The Clinical Trial
Design and Development subgroup's goals were to (1) define key considerations in the
design of clinical trials for cNF,(2) summarize existing data in relation to these
considerations, and (3) provide consensus recommendations about key elements of trial
design to accelerate the clinical development of therapies for cNF. Methods The subgroup …
conducted; however, none has resulted in meaningful changes to care. The Clinical Trial
Design and Development subgroup's goals were to (1) define key considerations in the
design of clinical trials for cNF,(2) summarize existing data in relation to these
considerations, and (3) provide consensus recommendations about key elements of trial
design to accelerate the clinical development of therapies for cNF. Methods The subgroup …
Objective
Several clinical trials targeting cutaneous neurofibromas (cNF) have been conducted; however, none has resulted in meaningful changes to care. The Clinical Trial Design and Development subgroup's goals were to (1) define key considerations in the design of clinical trials for cNF, (2) summarize existing data in relation to these considerations, and (3) provide consensus recommendations about key elements of trial design to accelerate the clinical development of therapies for cNF.
Methods
The subgroup, with experts from genetics, dermatology, neurology, oncology, and basic science, spanning academia, government research, and regulatory programs, and industry, reviewed published and unpublished data on clinical trials for cNF and other diseases in the skin. Discussions of these data resulted in formulation of a list of priority issues to address in order to develop efficient and effective clinical trials for cNF.
Results
The subgroup identified 2 natural history studies of cNF, 4 priority outcome measures, and 6 patient-reported outcome tools for potential use in efficacy trials of cNF. Time to initiate intervention, patient eligibility, mechanism of action, route of administration, safety monitoring, and regulatory agency interactions were identified as key factors to consider when designing clinical trials for cNF.
Conclusions
Alignment on endpoints and methods for the measurement and quantification of cNF represent a priority for therapeutic development for cNF. Advances in technological methods and outcome tools utilized in other skin diseases may be applicable to cNF studies. Patient age is an important factor guiding trial design and clinical development path.
American Academy of Neurology